What is the dosing guidance for Amitiza (lubiprostone) in a patient with irritable bowel syndrome with constipation (IBS‑C)?

Amitiza Dosing for IBS-C

For irritable bowel syndrome with constipation (IBS-C), the FDA-approved dose of Amitiza (lubiprostone) is 8 mcg orally twice daily, taken with food and water. 1

Key Dosing Details

Standard Dosing

• 8 mcg twice daily is the established dose for IBS-C 2, 1
• Take with food and water to reduce nausea 1
• Swallow capsules whole—do not break apart or chew 1

FDA Approval Specifics

• Approved specifically for women ≥18 years old with IBS-C 1
• This differs from the chronic idiopathic constipation indication (24 mcg twice daily for both men and women) 2

Dosage Adjustments for Hepatic Impairment

The dosing remains straightforward for most IBS-C patients, but requires modification in hepatic disease:

• Moderate hepatic impairment (Child-Pugh Class B): No adjustment necessary 1
• Severe hepatic impairment (Child-Pugh Class C): Reduce to 8 mcg once daily (if tolerated, can escalate to twice daily with appropriate monitoring) 1

Clinical Context from Guidelines

The 2022 AGA guidelines provide a conditional recommendation with moderate certainty for lubiprostone use in IBS-C 2. The evidence shows:

• Lubiprostone demonstrated superiority over placebo for global response and abdominal pain relief, though improvements didn't always meet thresholds for being clinically meaningful 2
• The drug was well-tolerated for up to 13 months in long-term studies 2
• Discontinuation rates due to adverse events were similar between lubiprostone (12.8%) and placebo (12.3%) 2

The 2021 British Society of Gastroenterology guidelines similarly recommend lubiprostone as an efficacious second-line drug for IBS-C (strong recommendation, moderate quality evidence), noting it's less likely to cause diarrhea than other secretagogues but warning that nausea is a frequent side effect 3.

Important Safety Considerations

Common Adverse Effects

• Nausea occurs in approximately 8% of IBS-C patients (vs 4% with placebo) 1
• Diarrhea occurs in approximately 7% (vs 4% with placebo) 1
• Taking with food significantly reduces nausea 1

Serious but Rare Risks

• Syncope and hypotension: Can occur within an hour of first dose or with subsequent doses; instruct patients to discontinue and contact you if this occurs 1
• Dyspnea: May occur within an hour of first dose, generally resolves within 3 hours 1
• Severe diarrhea: Instruct patients to discontinue if this develops 1

Contraindications

• Mechanical gastrointestinal obstruction (known or suspected) 1

Practical Management Algorithm

1. Confirm diagnosis: IBS-C in a woman ≥18 years old
2. Screen for contraindications: Rule out mechanical obstruction
3. Check liver function: Adjust dose only if Child-Pugh Class C
4. Initiate: 8 mcg twice daily with food and water
5. Counsel patient:
   • Take with meals to minimize nausea
   • Expect possible mild nausea or diarrhea initially
   • Discontinue and call if severe diarrhea, syncope, or dyspnea occurs
6. Reassess periodically: Evaluate need for continued therapy 1

Clinical Pitfalls to Avoid

• Don't use the 24 mcg dose for IBS-C—this is the chronic idiopathic constipation dose and increases adverse effects without additional benefit in IBS-C 2, 1
• Don't prescribe for men with IBS-C—FDA approval is limited to women, though this reflects study populations rather than proven inefficacy 1
• Don't forget food administration—taking without food significantly increases nausea rates 1
• Don't overlook hepatic impairment—severe liver disease requires dose reduction 1